Tumor News and Research

RSS

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Biochemists identify protein that can slow down growth of brain tumors in mice

Much like using dimmer switches to brighten or darken rooms, biochemists have identified a protein that can be used to slow down or speed up the growth of brain tumors in mice.

12 May 2014

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Molecular imaging aims at the visualization of molecules or molecular events that occur at the cellular level. Clearly it also allows the possibility of looking inside the biochemical pathway at the cellular level and therefore enables us to look at the onset of diseases well before they are resolved into structural change.

From Bruker BioSpin - NMR, EPR and Imaging 12 May 2014

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Whitehead Institute scientists have identified a genetic cause of a facial disorder known as hemifacial microsomia (HFM). The researchers find that duplication of the gene OTX2 induces HFM, the second-most common facial anomaly after cleft lip and palate.

12 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

Experimental antibody temporarily halts progression of neuroblastoma in children

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.

9 May 2014

Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers.

9 May 2014

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

A new paper by a team of researchers led by Zachary T. Schafer, Coleman Assistant Professor of Cancer Biology in the Department of Biological Sciences at the University of Notre Dame, offers important new insights into the role carcinoma-associated fibroblasts (CAFs) play in tumor biology.

9 May 2014

Study provides potential target for cutting off growth of cancer stem cells

A subset of immune cells directly target colon cancers, rather than the immune system, giving the cells the aggressive properties of cancer stem cells.

9 May 2014

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut.

9 May 2014

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells-those that can form breast tissue-alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

8 May 2014

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Bioengineers at the University of Rome Tor Vergata and the University of Montreal have used DNA to develop a tool that detects and reacts to chemical changes caused by cancer cells and that may one day be used to deliver drugs to tumor cells.

8 May 2014

Molecular subtyping provides insights into how to treat breast cancer

New evidence showing that the MammaPrint® and BluePrint® tests provide insights into how to treat breast cancer was presented at the annual conference of the American Society of Breast Surgeons (ASBrS).

7 May 2014

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins will use a $65 million gift toward the construction of a new patient care building that will be named for the late Albert P. “Skip” Viragh, Jr., a Maryland mutual fund investment leader and philanthropist.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

Rice University researchers find new possibilities for benign, 'tunable' virus

Rice University scientists have designed a tunable virus that works like a safe deposit box. It takes two keys to open it and release its therapeutic cargo.

7 May 2014

Tumor News and Research

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Biochemists identify protein that can slow down growth of brain tumors in mice

Molecular imaging and multimodality: an interview with Professor Silvio Aime, University of Turin

Whitehead Institute scientists identify genetic cause of hemifacial microsomia

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Experimental antibody temporarily halts progression of neuroblastoma in children

Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

Study provides potential target for cutting off growth of cancer stem cells

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Study finds ovarian cancer cells are more aggressive on soft tissues due to mechanical properties of environment

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

Bioengineers develop tool that reacts to chemical changes caused by cancer cells

Molecular subtyping provides insights into how to treat breast cancer

Johns Hopkins to use $65 million gift to expand Sidney Kimmel Comprehensive Cancer Center

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

Rice University researchers find new possibilities for benign, 'tunable' virus

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News